Vaccine Development, Innovations and Investments Oslo Malaria Conference, “Getting To Zero” Jean Stéphenne, Chairman and President GlaxoSmithKline Biologicals 12 April 2011

Value Of Vaccines 5m+ Future Deaths Prevented by GAVI Source: GAVI Alliance Website Source: Global Health Council Website (2008) Other Infections 9% Malaria, 8% Diarrhea 14% NCDs 4% Meningitis 2% AIDS, 2% Pertussis 2% Measles 1% Injury 3% Congenital Abnormalities 1% Neonatal Causes, 41% Pneumonia 14% Causes of Child Deaths  Vaccines are one of the most successful and cost-effective public health interventions o 30 vaccine preventable diseases o Save approximately 2.5 million lives each year o Support economic development, improve health, and increase productivity  Vaccines led to smallpox eradication in 1980; brought polio eradication within reach  EPI increased vaccine coverage from 20% in 1980 to 75% in 1990; with other interventions, annual child deaths decreased by 4 million  Great progress has been made, but more than 2 million children still die of vaccine- preventable diseases each year

GSK’s Approach To Developing And Delivering Vaccines Discovery Pre-clinical 3-5 years Up to $10m Clinical Process development/ Production capacity 2-3 years Up to $50m Registration Marketing/Distribution 2-5 years Up to $500m Vaccine development requires significant time and investment – R&D and access mechanisms help ensure they are developed and distributed Concept Product  Product development partnerships (MVI, IAVI, Aeras)  Partnerships with key multilateral agencies (GAVI, UNICEF)  Innovative access mechanisms: o Pneumo Advance Market Commitment o Fiocruz tech transfer (pneumo, rota, MMR, Hib); joint R&D venture for dengue  Tiered pricing: o Vaccines priced according to countries’ ability to pay; poorest countries pay lowest prices

GSK Works In Partnership To Fight Malaria  RTS,S, P. falciparum malaria vaccine candidate: o Reached full enrolment of Phase III trial in Africa; initial results (5- 17 months of age) expected Q o Developed in partnership with PATH Malaria Vaccine Initiative, Bill & Melinda Gates Foundation, African researchers and others o More than 25 years of research, including more than 10 years of clinical trials in sub-Saharan Africa o Could complement existing malaria interventions  Broader malaria commitments: o Working with Crucell and WRAIR on 2 nd gen P. falciparum vaccine candidate; R&D on vaccines for P. vivax o Sharing compounds to facilitate drug development o Developing drugs for P. vivax and drug-resistant P. falciparum in partnership with Medicines for Malaria Venture o Partnership with Norwegian Red Cross to distribute bed nets and treatment, increase prevention awareness and train health workers o Collaborations with local NGOs in sub-Saharan Africa

Vaccine Development, Innovations and Investments Oslo Malaria Conference, “Getting To Zero” Jean Stéphenne, Chairman and President GlaxoSmithKline Biologicals 12 April 2011